| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 01/09/2003 | WO2003002765A2 Methods for the diagnosis of cancer based on the obcam and ntm genes |
| 01/09/2003 | WO2003002755A2 Glaucoma treatments with reduced hyperpigmentation |
| 01/09/2003 | WO2003002742A1 Nucleic acid participating in the formation of presenilin-2-gene exon 5-defective splicing variant |
| 01/09/2003 | WO2003002739A1 Antisense oligonucleotide against human acetylcholinesterase (ache) and uses thereof |
| 01/09/2003 | WO2003002713A2 Antibodies to opgl |
| 01/09/2003 | WO2003002596A2 Use of dipeptidyl peptidase iv inhibitors as therapeutics for neurological disorders |
| 01/09/2003 | WO2003002595A2 Dipeptidyl peptidase iv inhibitors and their uses as anti-cancer agents |
| 01/09/2003 | WO2003002592A1 Aptamers and antiaptamers |
| 01/09/2003 | WO2003002584A1 NOVEL GALACTOSYLCERAMIDE ANALOGS AND β-GLUCOCEREBROSIDASE ACTIVATORS, EXTERNAL SKIN PREPARATIONS AND METHOD OF ACTIVATING β-GLUCOCEREBROSIDASE USING THE ANALOGS |
| 01/09/2003 | WO2003002580A1 6-`2-(phosphonomethoxy)alkoxy pyrimidine derivatives having antiviral activity |
| 01/09/2003 | WO2003002575A1 3-ARYL-$G(a)-OXY SUBSTITUTED PROPANOIC ACIDS AND A PROCESS FOR THEIR PREPARATION |
| 01/09/2003 | WO2003002571A1 Aryl boronate functionalized polymers for treating obesity |
| 01/09/2003 | WO2003002570A1 Aryl boronic acids for treating obesity |
| 01/09/2003 | WO2003002569A1 Method of inhibiting ptp 1b and/or t-cell ptp and/or other ptpases with an asp residue at position 48 |
| 01/09/2003 | WO2003002568A1 Carbohydrate derivatives |
| 01/09/2003 | WO2003002567A1 New pyrazolo[3,4-d]pyrimidines inhibiting h. pylori infections |
| 01/09/2003 | WO2003002566A1 Purine derivatives as a2b adenosine receptor antagonists |
| 01/09/2003 | WO2003002565A1 2,6,9-substituted purine derivatives and their use n the treatment of proliferative disorders |
| 01/09/2003 | WO2003002563A1 Pyrido-pyrido-pyrrolo pyrrolo-indole and pyrido-pyrrolo pyrrolo carbazole derivatives, method for the production thereof and pharmaceutical compositions containing said derivatives |
| 01/09/2003 | WO2003002561A1 N-aroyl cyclic amine derivatives as orexin receptor antagonists |
| 01/09/2003 | WO2003002560A1 New derivatives of oxazolidinones as antibacterial agents |
| 01/09/2003 | WO2003002559A2 Piperidine compounds for use as orexin receptor antagonist |
| 01/09/2003 | WO2003002558A1 Remedial agent for viral infectious disease |
| 01/09/2003 | WO2003002556A1 Novel heteroaryl derivatives, their preparation and use |
| 01/09/2003 | WO2003002555A1 Methods of using soluble epoxide hydrolase inhibitors |
| 01/09/2003 | WO2003002554A1 Piperazine compounds |
| 01/09/2003 | WO2003002553A2 Fluoropyrrolidines as dipeptidyl peptidase inhibitors |
| 01/09/2003 | WO2003002552A1 Novel indole derivatives |
| 01/09/2003 | WO2003002549A1 Eurotinone and derivatives thereof, method for the production and use of the same |
| 01/09/2003 | WO2003002544A1 N-heterocyclic inhibitors of tnf-alpha expression |
| 01/09/2003 | WO2003002541A1 Pyridazinone |
| 01/09/2003 | WO2003002535A1 Cyclic diamine compounds bearing six-membered cyclic groups |
| 01/09/2003 | WO2003002533A1 Triamide-substituted indoles, benzofuranes and benzothiophenes as inhibitors of microsomal triglyceride transfer protein (mtp) and/or apolipoprotein b (apo b) secretion |
| 01/09/2003 | WO2003002532A1 Cyclic diamine compounds having fused-ring groups |
| 01/09/2003 | WO2003002531A2 Fluoropyrrolidines as dipeptidyl peptidase inhibitors |
| 01/09/2003 | WO2003002530A2 Pyrrolidines as dipeptidyl peptidase inhibitors |
| 01/09/2003 | WO2003002528A2 Compositions and methods for inhibiting human immunodeficiency virus infection by down-regulating human cellular genes |
| 01/09/2003 | WO2003002524A2 Urea derivatives with antiproteolytic activity |
| 01/09/2003 | WO2003002522A1 Peptide deformylase inhibitors |
| 01/09/2003 | WO2003002510A1 Crystalline form of a phenylethanolamine, the preparation thereof and pharmaceutical compositions comprising the same |
| 01/09/2003 | WO2003002503A1 Thienothiazine compounds having anti-inflammatory and analgesic activities and their preparation methods and the use there of |
| 01/09/2003 | WO2003002495A1 Novel treatment of adrenocortical hypersecretion and tumour growth |
| 01/09/2003 | WO2003002202A1 Antitumoral formulations of thioxanthenone |
| 01/09/2003 | WO2003002175A2 Enhanced systemic absorption of intradermally delivered substances |
| 01/09/2003 | WO2003002155A1 Vector encoding human globlin gene and use thereof in treatment of hemoglobinopathies |
| 01/09/2003 | WO2003002153A1 Composition and method for reducing adverse interactions between phenothiazine derivatives and plasma using cyclodextrins |
| 01/09/2003 | WO2003002149A2 Use of pigment such as e.g. titanium dioxide for obtaining a special optical effect on oral medicament or food |
| 01/09/2003 | WO2003002148A1 Compositions and methods for prophylactic and therapeutic supplementation of nutrition in subjects |
| 01/09/2003 | WO2003002146A1 Medicinal compositions |
| 01/09/2003 | WO2003002145A1 Diagnosis and treatment of insulin-dependent diabetes mellitus and insulitis |
| 01/09/2003 | WO2003002137A2 Trp1, mct, or ftz-f1 homologous proteins involved in the regulation of energy homeostasis |
| 01/09/2003 | WO2003002130A1 Fat-binding polymers |
| 01/09/2003 | WO2003002129A1 Use of sulodexide for the treatment of inflammatory bowel disease |
| 01/09/2003 | WO2003002128A1 Methods and compositions for treatment of gastric diseases |
| 01/09/2003 | WO2003002127A1 Use of at least one glycoinhibitor substance |
| 01/09/2003 | WO2003002126A1 Anti-retroviral agent in combination with tea polyphenol for the treatment of viral infections |
| 01/09/2003 | WO2003002125A2 Combination of aminosugars and cysteine or cysteine derivatives |
| 01/09/2003 | WO2003002124A1 USE OF BIS-ACID(5-ANDROSTEN-17-ONE-3β-HYDROXYL) DIESTERS FOR MANUFACTURE PHARMACEUTICALS |
| 01/09/2003 | WO2003002123A2 Therapeutic combinations for the treatment of hormone deficiencies |
| 01/09/2003 | WO2003002122A1 Beta-hydroxyamine derivatives useful in treatment of alzheimer's disease |
| 01/09/2003 | WO2003002119A1 Treatment and prevention of lipodermatosclerosis |
| 01/09/2003 | WO2003002118A1 Substituted 8-arylquinoline pde4 inhibitors |
| 01/09/2003 | WO2003002117A2 Niaciamide and derivatives in combination with aminosugar |
| 01/09/2003 | WO2003002116A1 Zonisamide use in headache |
| 01/09/2003 | WO2003002115A2 Substituted benzimidazoles for controlling endoparasites |
| 01/09/2003 | WO2003002114A2 Use of potent, selective and non toxic c-kit inhibitors for treating mastocytosis |
| 01/09/2003 | WO2003002113A1 Vitamin c compositions |
| 01/09/2003 | WO2003002112A1 Erucamide compounds for the treatment and prevention to disturbances of the secretory system |
| 01/09/2003 | WO2003002111A1 Inhalation particles |
| 01/09/2003 | WO2003002110A1 METHODS FOR PREPARATION AND USE OF 1α,24(S)-DIHYDROXYVITAMIN D¿2? |
| 01/09/2003 | WO2003002109A2 Use of tyrosine kinase inhibitors for treating autoimmune diseases |
| 01/09/2003 | WO2003002108A2 Use of tyrosine kinase inhibitors for treating inflammatory diseases |
| 01/09/2003 | WO2003002107A2 Use of tyrosine kinase inhibitors for treating multiple sclerosis (ms) |
| 01/09/2003 | WO2003002106A2 Use of tyrosine kinase inhibitions for treating allergic diseases |
| 01/09/2003 | WO2003002105A2 Use of tyrosine kinase inhibitors for treating bone loss |
| 01/09/2003 | WO2003002104A2 Use of corrinoids in the treatment of skin diseases |
| 01/09/2003 | WO2003002103A2 Hydrophobic dopamine agonists administered to the dermis |
| 01/09/2003 | WO2003002102A1 Sustained release pharmaceutical composition |
| 01/09/2003 | WO2003002101A1 Oral pharmaceutical compositions with improved bioavailability |
| 01/09/2003 | WO2003002098A1 Tablet comprising cetirizine and pseudoephedrine |
| 01/09/2003 | WO2003002096A1 Methods and compositions for polyene antibiotics with reduced toxicity |
| 01/09/2003 | WO2003002094A2 Enhanced pharmacokinetic profile of hydrophobic substances |
| 01/09/2003 | WO2003002093A1 Olopatadine formulations for topical administration |
| 01/09/2003 | WO2003002085A1 Use of purified, water-soluble xylans extracted from palmaria |
| 01/09/2003 | WO2003002071A2 Individualized addiction cessation therapy |
| 01/09/2003 | WO2003002065A2 Hcv e1e2 vaccine compositions |
| 01/09/2003 | WO2003002064A2 Fused pyrimidine dhfr inhibitors as antibacterials |
| 01/09/2003 | WO2003002062A2 Bis-aryl thiazole derivatives |
| 01/09/2003 | WO2003002060A2 Method of treating malignancy associated hypercalcemia using active vitamin d analogues |
| 01/09/2003 | WO2003002059A2 Tolterodine metabolites |
| 01/09/2003 | WO2003002058A2 Bone anabolic compounds and methods of use |
| 01/09/2003 | WO2003001982A2 Physiological tissue repair and functional organ regeneration by cultivation of regenerative stem cells in vivo and in situ |
| 01/09/2003 | WO2003001968A2 Compositions and methods for inhibiting platelet activation and thrombosis |
| 01/09/2003 | WO2003001907A1 Nmp35 apoptosis inhibitor gene disruptions compositions and methods related thereto |
| 01/09/2003 | WO2003001887A2 Fused pyrimidines as d-alanyl-d-alanine ligase inhibitors |
| 01/09/2003 | WO2003001881A2 Cell-based high-throughput screening methods |
| 01/09/2003 | WO2002098345A8 Use of an antioxidant for treating and/or preventing surface ocular disorders |
| 01/09/2003 | WO2002087591A3 Use of derivatives of spironolactone like canrenone as anti-fibrogegic drug |
| 01/09/2003 | WO2002083674A3 Compositions containing imidazotriazinone for nasal application |
| 01/09/2003 | WO2002081020A3 Method for preventing acute renal failure |